AbelZeta Pharma 
Welcome,         Profile    Billing    Logout  
 15 Products   6 Diseases   15 Products   29 Trials   345 News 


«12345»
  • ||||||||||  trovocabtagene autoleucel (C-CAR088) / AbelZeta Pharma
    Enrollment open, Trial completion date, Trial primary completion date:  A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma (clinicaltrials.gov) -  May 14, 2019   
    P1,  N=10, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2019 --> Oct 2019
  • ||||||||||  C-CAR011 / AbelZeta Pharma
    Trial completion date, Trial primary completion date:  Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL (clinicaltrials.gov) -  Feb 25, 2019   
    P1,  N=10, Recruiting, 
    This possible effectiveness warrants further investigation of GM.CD40L in combination approaches. Trial completion date: May 2018 --> May 2020 | Trial primary completion date: May 2017 --> May 2019
  • ||||||||||  GM.CD40L cell vaccine / AbelZeta Pharma, H. Lee Moffitt Cancer Center and Research Institute
    Trial completion, Trial completion date, Combination therapy, Metastases:  Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer (clinicaltrials.gov) -  Feb 21, 2019   
    P1/2,  N=73, Completed, 
    Trial completion date: May 2018 --> May 2020 | Trial primary completion date: May 2017 --> May 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Feb 2019
  • ||||||||||  C-CAR011 / AbelZeta Pharma
    Trial completion, Trial completion date, Trial primary completion date, CAR T-Cell Therapy:  A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects (clinicaltrials.gov) -  Jan 17, 2019   
    P1,  N=15, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Feb 2019 Recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2019 | Trial primary completion date: Nov 2017 --> Sep 2018
  • ||||||||||  ReJoin (human adipose-derived mesenchymal progenitor cells) / Cellular Biomedicine
    Enrollment closed, Trial completion date, Trial primary completion date:  Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects (clinicaltrials.gov) -  Dec 17, 2018   
    P2,  N=28, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2019 | Trial primary completion date: Nov 2017 --> Sep 2018 Recruiting --> Active, not recruiting | Trial completion date: Dec 2016 --> Dec 2019 | Trial primary completion date: Dec 2016 --> Dec 2019
  • ||||||||||  C-CAR011 / Cellular Biomedicine
    Trial completion date, Trial initiation date, Trial primary completion date, CAR T-Cell Therapy:  C-CAR011 Treatment in Subjects With ALL After HSCT (clinicaltrials.gov) -  Sep 25, 2018   
    P=N/A,  N=40, Not yet recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2016 --> Dec 2019 | Trial primary completion date: Dec 2016 --> Dec 2019 Trial completion date: Dec 2019 --> Apr 2021 | Initiation date: May 2018 --> Oct 2018 | Trial primary completion date: Oct 2019 --> Feb 2021
  • ||||||||||  GM.CD40L cell vaccine / AbelZeta Pharma, H. Lee Moffitt Cancer Center and Research Institute
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung (clinicaltrials.gov) -  Jun 27, 2018   
    P1/2,  N=0, Withdrawn, 
    Trial completion date: Dec 2018 --> Mar 2019 N=100 --> 0 | Trial completion date: Dec 2020 --> Jul 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2019 --> Jul 2019
  • ||||||||||  GM.CD40L cell vaccine / AbelZeta Pharma, H. Lee Moffitt Cancer Center and Research Institute
    Trial completion date, Combination therapy, Metastases:  Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer (clinicaltrials.gov) -  Jun 8, 2018   
    P1/2,  N=73, Active, not recruiting, 
    N=100 --> 0 | Trial completion date: Dec 2020 --> Jul 2020 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2019 --> Jul 2019 Trial completion date: Dec 2018 --> Dec 2019
  • ||||||||||  C-CAR011 / Cellular Biomedicine
    Trial completion date, Trial initiation date, Trial primary completion date, CAR T-Cell Therapy:  C-CAR011 Treatment in Subjects With ALL After HSCT (clinicaltrials.gov) -  Apr 19, 2018   
    P=N/A,  N=40, Not yet recruiting, 
    Trial completion date: Jun 2018 --> Jun 2019 Trial completion date: Jun 2019 --> Dec 2019 | Initiation date: Oct 2017 --> May 2018 | Trial primary completion date: Dec 2018 --> Oct 2019
  • ||||||||||  GM.CD40L cell vaccine / AbelZeta Pharma, H. Lee Moffitt Cancer Center and Research Institute
    Trial initiation date:  Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung (clinicaltrials.gov) -  Mar 3, 2018   
    P1/2,  N=100, Not yet recruiting, 
    Trial completion date: Jun 2019 --> Dec 2019 | Initiation date: Oct 2017 --> May 2018 | Trial primary completion date: Dec 2018 --> Oct 2019 Initiation date: Feb 2018 --> Apr 2018
  • ||||||||||  GM.CD40L cell vaccine / Cellular Biomedicine, H. Lee Moffitt Cancer Center and Research Institute
    Trial initiation date, Combination therapy, Metastases:  Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer (clinicaltrials.gov) -  Jan 3, 2018   
    P1/2,  N=73, Active, not recruiting, 
    Trial primary completion date: Mar 2017 --> Apr 2018 | Trial completion date: Jul 2017 --> Apr 2018 Initiation date: Oct 2012 --> Mar 2012
  • ||||||||||  C-CAR011 / Cellular Biomedicine
    New trial, CAR T-Cell Therapy:  C-CAR011 Treatment in Subjects With ALL After HSCT (clinicaltrials.gov) -  Oct 31, 2017   
    P=N/A,  N=40, Not yet recruiting,